WebNov 10, 2024 · Males and females 2 to less than18 years old and weighing at least 10 kg. Having a pathology report that confirms colonic inflammation consistent with UC with a clinical diagnosis of UC for at least 12 weeks prior to baseline, with biopsy report supporting the diagnosis of UC. WebFeb 27, 2024 · The trial is now active at the University of Texas MD Anderson Cancer Center. IMNN-001 is a DNA-based interleukin-12 (IL-12) immunotherapy currently in Phase 2 clinical development for the localized treatment of …
Celsion Corporation Initiates Phase II OVATION 2 Study of
WebAug 17, 2024 · In this randomized, open-label study known as OVATION 2, investigators will evaluate the safety and effectiveness of GEN-1, an experimental DNA-mediated interleukin-12 (IL-12) immunotherapy, given with standard-of-care NACT ( paclitaxel and carboplatin ) compared to NACT and surgery alone. WebFeb 22, 2024 · Data for the phase 1 portion of the OVATION 2 trial was shared with the FDA prior to the fast track designation, finding a complete tumor resection was achieved in 7 … hint icon png
How to Get Started - OvationVR
WebJul 5, 2024 · In the trial, people with metastatic breast cancer who were treated with the HER2-targeted drug trastuzumab deruxtecan ... that they gave Dr. Modi a standing ovation. Drug delivers chemotherapy payload to tumor cells. T-DXd, which is given by infusion into a vein, is a type of drug known as an antibody–drug conjugate. WebJun 18, 2024 · CLSN is currently conducting the Phase 1/2 OVATION 2 study of GEN-1 (the company's lead immunotherapy development product) in advanced stage (Stage III/IV) ovarian cancer. The company... WebSep 20, 2024 · The randomized, open-label, multicenter OVATION 2 trial (NCT03393884) is evaluating the dosing, safety, efficacy, and biological activity of the investigational agent … hint icon